ERBB2 and neoplasm: Clinicopathological variables such as tumour size, tumour grade and nodal status together with immunohistochemistry (IHC) markers e.g. estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) are conventionally used for patient prognosis and therapeutic decision2.